Please assess the completion status of the following clinical trial:

Trial Title: STOPping Versus Continuing Antiplatelet Therapy During Noncardiac Surgery and Procedures After Next Generation Drug-eluting Stent Implantation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 19-85 years~* Planning of elective noncardiac surgery or invasive procedure~* At least 1 year interval between the surgery or procedure and last PCI with next generation DES~* Currently on antiplatelet therapy~Exclusion Criteria:~* PCI with BMS(bare metal stent), 1st generation DES or bioresorbable vascular scaffold~* Total length of inserted DES in the 3 vessels \>60 mm~* History of stent thrombosis~* History of coronary artery bypass grafting surgery~* Planned surgery or procedure with high bleeding risk including followings: intracranial neurosurgery, spinal canal surgery, and eye posterior chamber surgery, endoscopic mucosal resection (EMR), endoscopic submucosal dissection (ESD), ampullary resection, endoscopic retrograde cholangiopancreatography (ERCP) with endoscopic sphincterotomy plus large-balloon papillary dilation, endoscopic ultrasonography-guided fine-needle aspiration (EUS-FNA) of cystic lesions~* Left ventricular ejection fraction \<40%~* Myocardial infarction within 6 months~* Any overt thromboembolism requiring medical surveillance and/or treatment~* Any clinically overt sign of hemorrhage within 3 months~* Anticoagulant therapy for any reason~* Need of continuation or discontinuation of antiplatelet therapy during surgery or procedure at the discretion of cardiologist or operator~* Any contraindication, adverse drug reaction or hypersensitivity to aspirin~* Pregnant women or women with potential childbearing~* Inability to understand or read the informed content

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Continuing aspirin (Type: ACTIVE_COMPARATOR): Patients in the group may continue the administration of aspirin during perioperative period.
- Stopping aspirin (Type: EXPERIMENTAL): Patients in the group may stop medication of antiplatelet drugs during perioperative period.

Based on this trial design, predict the completion outcome and termination type (if applicable).